Acer Therapeutics ACER Stock
Acer Therapeutics Price Chart
Acer Therapeutics ACER Financial and Trading Overview
Acer Therapeutics stock price | 0.9 USD |
Previous Close | 0.98 USD |
Open | 1 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1000 |
Day's Range | 0.86 - 1 USD |
52 Week Range | 0.65 - 4.56 USD |
Volume | 295.66K USD |
Avg. Volume | 361.75K USD |
Market Cap | 21.19M USD |
Beta (5Y Monthly) | 0.579521 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11 USD |
ACER Valuation Measures
Enterprise Value | 45.68M USD |
Trailing P/E | N/A |
Forward P/E | 7.266667 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -2.031 |
Trading Information
Acer Therapeutics Stock Price History
Beta (5Y Monthly) | 0.579521 |
52-Week Change | -50.56% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.56 USD |
52 Week Low | 0.65 USD |
50-Day Moving Average | 0.89 USD |
200-Day Moving Average | 1.55 USD |
ACER Share Statistics
Avg. Volume (3 month) | 361.75K USD |
Avg. Daily Volume (10-Days) | 272.97K USD |
Shares Outstanding | 24.3M |
Float | 16M |
Short Ratio | 4 |
% Held by Insiders | 14.29% |
% Held by Institutions | 31.84% |
Shares Short | 811.87K |
Short % of Float | 4.45% |
Short % of Shares Outstanding | 3.33% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 96:1000 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -59.80% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -22495344 USD |
Net Income Avi to Common (ttm) | -33339016 USD |
Diluted EPS (ttm) | -1.67 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 6.38M USD |
Total Cash Per Share (mrq) | 0.26 USD |
Total Debt (mrq) | 28.68M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.2 |
Book Value Per Share (mrq) | -1.115 |
Cash Flow Statement
Operating Cash Flow (ttm) | -36256532 USD |
Levered Free Cash Flow (ttm) | -27714770 USD |
Profile of Acer Therapeutics
Country | United States |
State | MA |
City | Newton |
Address | One Gateway Center |
ZIP | 02458 |
Phone | 844 902 6100 |
Website | https://www.acertx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 33 |
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Q&A For Acer Therapeutics Stock
What is a current ACER stock price?
Acer Therapeutics ACER stock price today per share is 0.9 USD.
How to purchase Acer Therapeutics stock?
You can buy ACER shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Acer Therapeutics?
The stock symbol or ticker of Acer Therapeutics is ACER.
Which industry does the Acer Therapeutics company belong to?
The Acer Therapeutics industry is Biotechnology.
How many shares does Acer Therapeutics have in circulation?
The max supply of Acer Therapeutics shares is 0.
What is Acer Therapeutics Price to Earnings Ratio (PE Ratio)?
Acer Therapeutics PE Ratio is now.
What was Acer Therapeutics earnings per share over the trailing 12 months (TTM)?
Acer Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Acer Therapeutics company belong to?
The Acer Therapeutics sector is Healthcare.
Acer Therapeutics ACER included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 17601.05 USD — |
+0.87
|
8.38B USD — | 17181.27 USD — | 17716.52 USD — | — - | 8.38B USD — |
NASDAQ Capital Market Composite RCMP | 101.28 USD — |
+1.47
|
— — | 98.06 USD — | 101.88 USD — | — - | — — |
NASDAQ HealthCare IXHC | 942.47 USD — |
+1.43
|
— — | 920.56 USD — | 943.62 USD — | — - | — — |
- {{ link.label }} {{link}}